Review



e2f5  (Brickell Biotech)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Brickell Biotech e2f5
    Potential target genes of FZXYJD in E2F family were predicted. (A) <t>E2F5</t> has low expression in ccRCC. (B) Patients had poorer survival with low expression of E2F5 in ccRCC. (C-F) FZXYJD can increase the expression level of E2F5 in ccRCC cell line. *, P<0.05; **, P<0.01; ***, P<0.001. Control, cultured in SD rat serum. LD, cultured in FZXYJD lower dose group serum. MD, cultured in FZXYJD medium dose group serum. HD, cultured in FZXYJD high-dose group serum. ccRCC, clear cell renal cell carcinoma; FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction; HD, high-dose; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; LD, low-dose; MD, medium-dose; N, normal; SD, Sprague-Dawley; T, tumor; TPM, transcripts per million.
    E2f5, supplied by Brickell Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/e2f5/product/Brickell Biotech
    Average 86 stars, based on 1 article reviews
    e2f5 - by Bioz Stars, 2026-05
    86/100 stars

    Images

    1) Product Images from "Fu Zheng Xiao Yu San Jie Decoction affects the proliferation of renal cell carcinoma via regulating E2F5 gene"

    Article Title: Fu Zheng Xiao Yu San Jie Decoction affects the proliferation of renal cell carcinoma via regulating E2F5 gene

    Journal: Translational Andrology and Urology

    doi: 10.21037/tau-2025-aw-739

    Potential target genes of FZXYJD in E2F family were predicted. (A) E2F5 has low expression in ccRCC. (B) Patients had poorer survival with low expression of E2F5 in ccRCC. (C-F) FZXYJD can increase the expression level of E2F5 in ccRCC cell line. *, P<0.05; **, P<0.01; ***, P<0.001. Control, cultured in SD rat serum. LD, cultured in FZXYJD lower dose group serum. MD, cultured in FZXYJD medium dose group serum. HD, cultured in FZXYJD high-dose group serum. ccRCC, clear cell renal cell carcinoma; FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction; HD, high-dose; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; LD, low-dose; MD, medium-dose; N, normal; SD, Sprague-Dawley; T, tumor; TPM, transcripts per million.
    Figure Legend Snippet: Potential target genes of FZXYJD in E2F family were predicted. (A) E2F5 has low expression in ccRCC. (B) Patients had poorer survival with low expression of E2F5 in ccRCC. (C-F) FZXYJD can increase the expression level of E2F5 in ccRCC cell line. *, P<0.05; **, P<0.01; ***, P<0.001. Control, cultured in SD rat serum. LD, cultured in FZXYJD lower dose group serum. MD, cultured in FZXYJD medium dose group serum. HD, cultured in FZXYJD high-dose group serum. ccRCC, clear cell renal cell carcinoma; FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction; HD, high-dose; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; LD, low-dose; MD, medium-dose; N, normal; SD, Sprague-Dawley; T, tumor; TPM, transcripts per million.

    Techniques Used: Expressing, Control, Cell Culture

    E2F5 was involved in FZXYJD suppression of ccRCC cells proliferation. (A) Western blot and RT-qPCR were performed to analyze E2F5 expression in si E2F5 -transfected ccRCC cell line. β-actin was used as an internal quantitative control. (B) CCK-8 assay. (C) Cell colony formation assay [IPHONE X PRO MAX] (magnification: 1×; crystal violet stained). *, P<0.05; **, P<0.01; ***, P<0.001. CCK-8, Cell Counting Kit-8; ccRCC, clear cell renal cell carcinoma; FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction; NC, negative control; OD, optical density; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; si E2F5 , small interfering RNA targeting E2F5 .
    Figure Legend Snippet: E2F5 was involved in FZXYJD suppression of ccRCC cells proliferation. (A) Western blot and RT-qPCR were performed to analyze E2F5 expression in si E2F5 -transfected ccRCC cell line. β-actin was used as an internal quantitative control. (B) CCK-8 assay. (C) Cell colony formation assay [IPHONE X PRO MAX] (magnification: 1×; crystal violet stained). *, P<0.05; **, P<0.01; ***, P<0.001. CCK-8, Cell Counting Kit-8; ccRCC, clear cell renal cell carcinoma; FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction; NC, negative control; OD, optical density; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; si E2F5 , small interfering RNA targeting E2F5 .

    Techniques Used: Western Blot, Quantitative RT-PCR, Expressing, Transfection, Control, CCK-8 Assay, Colony Assay, Staining, Cell Counting, Negative Control, Reverse Transcription, Real-time Polymerase Chain Reaction, Small Interfering RNA

    Three-dimensional and two-dimensional docking patterns and interactions of FZXYSJD identified components with the E2F5 protein. FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction.
    Figure Legend Snippet: Three-dimensional and two-dimensional docking patterns and interactions of FZXYSJD identified components with the E2F5 protein. FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction.

    Techniques Used:



    Similar Products

    gene exp e2f5 hs00231092 m1  (Thermo Fisher)
    86
    Thermo Fisher gene exp e2f5 hs00231092 m1
    (a–d) Expression of (a) CYP3A4 , (b) LCT , (c) CXCL11 , and (d) <t>E2F5</t> , normalised to the lowest expression in the whole dataset and presented on a log 2 scale. The grey marker in group BiopsyDiag represents the misclassified biopsy from case 51, and the grey marker in group TGdiag represents the misclassified biopsy from case 55. From left to right in each plot, the groups are: Not CD, Normalised CD, Potential CD without progression, Potential CD with progression, Potential CD with high anti‐TG2 and progression, Biopsy‐based CD diagnosis, Anti‐TG2 based CD diagnosis, and Marsh 3 histopathology and negative anti‐TG2.
    Gene Exp E2f5 Hs00231092 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp e2f5 hs00231092 m1/product/Thermo Fisher
    Average 86 stars, based on 1 article reviews
    gene exp e2f5 hs00231092 m1 - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    kristian helin  (Addgene inc)
    92
    Addgene inc kristian helin
    (a–d) Expression of (a) CYP3A4 , (b) LCT , (c) CXCL11 , and (d) <t>E2F5</t> , normalised to the lowest expression in the whole dataset and presented on a log 2 scale. The grey marker in group BiopsyDiag represents the misclassified biopsy from case 51, and the grey marker in group TGdiag represents the misclassified biopsy from case 55. From left to right in each plot, the groups are: Not CD, Normalised CD, Potential CD without progression, Potential CD with progression, Potential CD with high anti‐TG2 and progression, Biopsy‐based CD diagnosis, Anti‐TG2 based CD diagnosis, and Marsh 3 histopathology and negative anti‐TG2.
    Kristian Helin, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/kristian helin/product/Addgene inc
    Average 92 stars, based on 1 article reviews
    kristian helin - by Bioz Stars, 2026-05
    92/100 stars
    		  Buy from Supplier
    pcmv ha e2f5  (Addgene inc)
    92
    Addgene inc pcmv ha e2f5
    (a–d) Expression of (a) CYP3A4 , (b) LCT , (c) CXCL11 , and (d) <t>E2F5</t> , normalised to the lowest expression in the whole dataset and presented on a log 2 scale. The grey marker in group BiopsyDiag represents the misclassified biopsy from case 51, and the grey marker in group TGdiag represents the misclassified biopsy from case 55. From left to right in each plot, the groups are: Not CD, Normalised CD, Potential CD without progression, Potential CD with progression, Potential CD with high anti‐TG2 and progression, Biopsy‐based CD diagnosis, Anti‐TG2 based CD diagnosis, and Marsh 3 histopathology and negative anti‐TG2.
    Pcmv Ha E2f5, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pcmv ha e2f5/product/Addgene inc
    Average 92 stars, based on 1 article reviews
    pcmv ha e2f5 - by Bioz Stars, 2026-05
    92/100 stars
    		  Buy from Supplier
    pcmvha e2f5  (Addgene inc)
    92
    Addgene inc pcmvha e2f5
    (a–d) Expression of (a) CYP3A4 , (b) LCT , (c) CXCL11 , and (d) <t>E2F5</t> , normalised to the lowest expression in the whole dataset and presented on a log 2 scale. The grey marker in group BiopsyDiag represents the misclassified biopsy from case 51, and the grey marker in group TGdiag represents the misclassified biopsy from case 55. From left to right in each plot, the groups are: Not CD, Normalised CD, Potential CD without progression, Potential CD with progression, Potential CD with high anti‐TG2 and progression, Biopsy‐based CD diagnosis, Anti‐TG2 based CD diagnosis, and Marsh 3 histopathology and negative anti‐TG2.
    Pcmvha E2f5, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pcmvha e2f5/product/Addgene inc
    Average 92 stars, based on 1 article reviews
    pcmvha e2f5 - by Bioz Stars, 2026-05
    92/100 stars
    		  Buy from Supplier
    e2f5  (Brickell Biotech)
    86
    Brickell Biotech e2f5
    Potential target genes of FZXYJD in E2F family were predicted. (A) <t>E2F5</t> has low expression in ccRCC. (B) Patients had poorer survival with low expression of E2F5 in ccRCC. (C-F) FZXYJD can increase the expression level of E2F5 in ccRCC cell line. *, P<0.05; **, P<0.01; ***, P<0.001. Control, cultured in SD rat serum. LD, cultured in FZXYJD lower dose group serum. MD, cultured in FZXYJD medium dose group serum. HD, cultured in FZXYJD high-dose group serum. ccRCC, clear cell renal cell carcinoma; FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction; HD, high-dose; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; LD, low-dose; MD, medium-dose; N, normal; SD, Sprague-Dawley; T, tumor; TPM, transcripts per million.
    E2f5, supplied by Brickell Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/e2f5/product/Brickell Biotech
    Average 86 stars, based on 1 article reviews
    e2f5 - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    anti e2f5  (Boster Bio)
    93
    Boster Bio anti e2f5
    Potential target genes of FZXYJD in E2F family were predicted. (A) <t>E2F5</t> has low expression in ccRCC. (B) Patients had poorer survival with low expression of E2F5 in ccRCC. (C-F) FZXYJD can increase the expression level of E2F5 in ccRCC cell line. *, P<0.05; **, P<0.01; ***, P<0.001. Control, cultured in SD rat serum. LD, cultured in FZXYJD lower dose group serum. MD, cultured in FZXYJD medium dose group serum. HD, cultured in FZXYJD high-dose group serum. ccRCC, clear cell renal cell carcinoma; FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction; HD, high-dose; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; LD, low-dose; MD, medium-dose; N, normal; SD, Sprague-Dawley; T, tumor; TPM, transcripts per million.
    Anti E2f5, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti e2f5/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    anti e2f5 - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    anti e2f5  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology anti e2f5
    Potential target genes of FZXYJD in E2F family were predicted. (A) <t>E2F5</t> has low expression in ccRCC. (B) Patients had poorer survival with low expression of E2F5 in ccRCC. (C-F) FZXYJD can increase the expression level of E2F5 in ccRCC cell line. *, P<0.05; **, P<0.01; ***, P<0.001. Control, cultured in SD rat serum. LD, cultured in FZXYJD lower dose group serum. MD, cultured in FZXYJD medium dose group serum. HD, cultured in FZXYJD high-dose group serum. ccRCC, clear cell renal cell carcinoma; FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction; HD, high-dose; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; LD, low-dose; MD, medium-dose; N, normal; SD, Sprague-Dawley; T, tumor; TPM, transcripts per million.
    Anti E2f5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti e2f5/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    anti e2f5 - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    (a–d) Expression of (a) CYP3A4 , (b) LCT , (c) CXCL11 , and (d) E2F5 , normalised to the lowest expression in the whole dataset and presented on a log 2 scale. The grey marker in group BiopsyDiag represents the misclassified biopsy from case 51, and the grey marker in group TGdiag represents the misclassified biopsy from case 55. From left to right in each plot, the groups are: Not CD, Normalised CD, Potential CD without progression, Potential CD with progression, Potential CD with high anti‐TG2 and progression, Biopsy‐based CD diagnosis, Anti‐TG2 based CD diagnosis, and Marsh 3 histopathology and negative anti‐TG2.

    Journal: Journal of Cellular and Molecular Medicine

    Article Title: Classification of Paediatric Celiac Disease Using RNA Sequencing and Real‐Time PCR of Duodenal Biomarkers

    doi: 10.1111/jcmm.70854

    Figure Lengend Snippet: (a–d) Expression of (a) CYP3A4 , (b) LCT , (c) CXCL11 , and (d) E2F5 , normalised to the lowest expression in the whole dataset and presented on a log 2 scale. The grey marker in group BiopsyDiag represents the misclassified biopsy from case 51, and the grey marker in group TGdiag represents the misclassified biopsy from case 55. From left to right in each plot, the groups are: Not CD, Normalised CD, Potential CD without progression, Potential CD with progression, Potential CD with high anti‐TG2 and progression, Biopsy‐based CD diagnosis, Anti‐TG2 based CD diagnosis, and Marsh 3 histopathology and negative anti‐TG2.

    Article Snippet: E2F5 , E2F transcription factor 5 , 8q21.2 , Hs00231092_m1.

    Techniques: Expressing, Marker, Biomarker Discovery, Histopathology

    Potential target genes of FZXYJD in E2F family were predicted. (A) E2F5 has low expression in ccRCC. (B) Patients had poorer survival with low expression of E2F5 in ccRCC. (C-F) FZXYJD can increase the expression level of E2F5 in ccRCC cell line. *, P<0.05; **, P<0.01; ***, P<0.001. Control, cultured in SD rat serum. LD, cultured in FZXYJD lower dose group serum. MD, cultured in FZXYJD medium dose group serum. HD, cultured in FZXYJD high-dose group serum. ccRCC, clear cell renal cell carcinoma; FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction; HD, high-dose; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; LD, low-dose; MD, medium-dose; N, normal; SD, Sprague-Dawley; T, tumor; TPM, transcripts per million.

    Journal: Translational Andrology and Urology

    Article Title: Fu Zheng Xiao Yu San Jie Decoction affects the proliferation of renal cell carcinoma via regulating E2F5 gene

    doi: 10.21037/tau-2025-aw-739

    Figure Lengend Snippet: Potential target genes of FZXYJD in E2F family were predicted. (A) E2F5 has low expression in ccRCC. (B) Patients had poorer survival with low expression of E2F5 in ccRCC. (C-F) FZXYJD can increase the expression level of E2F5 in ccRCC cell line. *, P<0.05; **, P<0.01; ***, P<0.001. Control, cultured in SD rat serum. LD, cultured in FZXYJD lower dose group serum. MD, cultured in FZXYJD medium dose group serum. HD, cultured in FZXYJD high-dose group serum. ccRCC, clear cell renal cell carcinoma; FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction; HD, high-dose; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; LD, low-dose; MD, medium-dose; N, normal; SD, Sprague-Dawley; T, tumor; TPM, transcripts per million.

    Article Snippet: It was then incubated overnight at 4 °C with the primary antibodies: E2F5 (1:1,000, Catalog: D197169, BBI, Shanghai, China) and β-Actin (1:1,000, Catalog: ab8227, Abcam, Shanghai, China).

    Techniques: Expressing, Control, Cell Culture

    E2F5 was involved in FZXYJD suppression of ccRCC cells proliferation. (A) Western blot and RT-qPCR were performed to analyze E2F5 expression in si E2F5 -transfected ccRCC cell line. β-actin was used as an internal quantitative control. (B) CCK-8 assay. (C) Cell colony formation assay [IPHONE X PRO MAX] (magnification: 1×; crystal violet stained). *, P<0.05; **, P<0.01; ***, P<0.001. CCK-8, Cell Counting Kit-8; ccRCC, clear cell renal cell carcinoma; FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction; NC, negative control; OD, optical density; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; si E2F5 , small interfering RNA targeting E2F5 .

    Journal: Translational Andrology and Urology

    Article Title: Fu Zheng Xiao Yu San Jie Decoction affects the proliferation of renal cell carcinoma via regulating E2F5 gene

    doi: 10.21037/tau-2025-aw-739

    Figure Lengend Snippet: E2F5 was involved in FZXYJD suppression of ccRCC cells proliferation. (A) Western blot and RT-qPCR were performed to analyze E2F5 expression in si E2F5 -transfected ccRCC cell line. β-actin was used as an internal quantitative control. (B) CCK-8 assay. (C) Cell colony formation assay [IPHONE X PRO MAX] (magnification: 1×; crystal violet stained). *, P<0.05; **, P<0.01; ***, P<0.001. CCK-8, Cell Counting Kit-8; ccRCC, clear cell renal cell carcinoma; FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction; NC, negative control; OD, optical density; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; si E2F5 , small interfering RNA targeting E2F5 .

    Article Snippet: It was then incubated overnight at 4 °C with the primary antibodies: E2F5 (1:1,000, Catalog: D197169, BBI, Shanghai, China) and β-Actin (1:1,000, Catalog: ab8227, Abcam, Shanghai, China).

    Techniques: Western Blot, Quantitative RT-PCR, Expressing, Transfection, Control, CCK-8 Assay, Colony Assay, Staining, Cell Counting, Negative Control, Reverse Transcription, Real-time Polymerase Chain Reaction, Small Interfering RNA

    Three-dimensional and two-dimensional docking patterns and interactions of FZXYSJD identified components with the E2F5 protein. FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction.

    Journal: Translational Andrology and Urology

    Article Title: Fu Zheng Xiao Yu San Jie Decoction affects the proliferation of renal cell carcinoma via regulating E2F5 gene

    doi: 10.21037/tau-2025-aw-739

    Figure Lengend Snippet: Three-dimensional and two-dimensional docking patterns and interactions of FZXYSJD identified components with the E2F5 protein. FZXYSJD, Fu Zheng Xiao Yu San Jie Decoction.

    Article Snippet: It was then incubated overnight at 4 °C with the primary antibodies: E2F5 (1:1,000, Catalog: D197169, BBI, Shanghai, China) and β-Actin (1:1,000, Catalog: ab8227, Abcam, Shanghai, China).

    Techniques: